Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2022

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table summarizes revenue by revenue source as follows:

	Three Months Ended March 31,
Major Products/Service Lines (in thousands)	2022		2021
Product revenue, net(1)	$	180,009	$	87,319
License and royalty revenues(2)	28,871		5,190
Total revenues	$	208,880	$	92,509

________________________________

(1)The Company’s principal products include PYLARIFY, DEFINITY and TechneLite and are categorized within product revenue, net. The Company applies the same revenue recognition policies and judgments for all its principal products.

(2)The Company recognized $24.0 million license revenue in the first quarter of 2022 related to an agreement with Novartis Pharma AG. Please refer to Note 19, “Commitments and Contingencies” for further details on the license agreement.

Revenue by product category on a net basis is as follows:

	Three Months Ended March 31,
(in thousands)	2022		2021
DEFINITY	$	58,328	$	55,971
TechneLite	22,605		22,800
Other precision diagnostics	5,265		6,984
Total precision diagnostics	86,198		85,755
PYLARIFY	92,777		—
Other radiopharmaceutical oncology	1,327		1,500
Total radiopharmaceutical oncology	94,104		1,500
Strategic partnerships and other revenue	28,578		5,254
Total revenues	$	208,880	$	92,509